(From the November 2016 issue of Research Now)
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health announced four new Centers of Research Translation (CORT) awards this year, including the Center of Research Translation in Muscular Dystrophy Therapeutic Development, led by Kevin Flanigan, MD, in The Research Institute at Nationwide Children's Hospital.
CORTs are team science programs designed to address translational research challenges in diseases or conditions within the mission of the NIAMS. The programs will build on basic research findings with the overarching goal of disease-specific translation.
Each CORT contains highly meritorious translational research projects, one or more research cores and an administrative core. Combined, the projects and cores will generate new knowledge to improve understanding of human pathophysiology. They aim to identify new therapeutic targets, develop more effective treatments or diagnostics, or design novel prevention strategies for human disease.
Muscular dystrophies are a group of genetic diseases that cause progressive muscle weakness and degeneration. The CORT program at Nationwide Children's seeks to accelerate the translation of genetic therapies to potentially treat some of the most common forms of muscular dystrophy, including Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy.